The pharmacology of Mounjaro: what tirzepatide actually does

The biggest misconception: Mounjaro is not simply a stronger version of Ozempic

Most people who arrive at a pharmacology question about Mounjaro already know it involves gut hormones. The misconception worth correcting first is the assumption that tirzepatide is just a more potent GLP-1 drug, an upgraded Ozempic. It is not. Semaglutide (Ozempic, Wegovy) targets a single receptor: GLP-1. Tirzepatide binds to two: GLP-1 and GIP. GIP stands for glucose-dependent insulinotropic polypeptide, a hormone released from the small intestine after eating. For years, pharmacologists debated whether activating the GIP receptor in the context of obesity would help or hinder, early research suggested GIP might even promote fat storage. What the SURMOUNT clinical programme demonstrated is that combining GIP and GLP-1 receptor activation produces a meaningfully different metabolic effect than either alone.

The result in practice: stronger appetite suppression, a more pronounced effect on gastric emptying, and (in the SURMOUNT-1 trial published in the New England Journal of Medicine) average weight reductions of around 20–21% at the 15 mg dose over 72 weeks. Those are figures from a controlled trial; individual responses vary, and a prescriber weighs your full picture before recommending tirzepatide at all. You can read more about the medicine's clinical background on our tirzepatide overview page.

What each receptor pathway actually does (and why the combination matters

The GLP-1 receptor is found in the pancreas, the gut wall, and) critically, in appetite-regulating centres in the brain. When tirzepatide binds it, the effects include: slowed gastric emptying (food moves more slowly from the stomach into the small intestine, extending the sensation of fullness), increased insulin secretion in proportion to blood-glucose levels, and reduced glucagon release. That last point matters for blood-sugar regulation: glucagon normally signals the liver to release stored glucose, so suppressing it helps keep post-meal spikes flatter.

The GIP receptor adds a different layer. GIP is secreted earlier in the meal response than GLP-1, making tirzepatide's pharmacokinetic profile more responsive to actual eating patterns. Current evidence suggests GIP receptor activation, in the context of simultaneous GLP-1 agonism, amplifies the satiety signal beyond what GLP-1 alone achieves and may improve tolerability, partly explaining why tirzepatide's gastrointestinal side-effect burden, while real, tends to be described as manageable at careful dose titration. For a detailed look at how the drug behaves over time in the body, the pharmacokinetics of tirzepatide page covers half-life, absorption and steady-state dosing.

The BNF entry for tirzepatide is the standard professional reference for prescribers in the UK and reflects the most current licensed indication and prescribing notes.

The dosing schedule and what it tells you about the pharmacology

Tirzepatide is injected once a week via a pre-filled KwikPen. The schedule begins at 2.5 mg, a dose the SmPC describes as a starter for tolerability, not a treatment dose. From there, a prescriber typically moves through 5, 7.5, 10, 12.5 and up to 15 mg in roughly four-week steps. The reason for that gradual titration is rooted in the mechanism: because the drug slows gastric emptying and acts on brainstem satiety centres, moving to therapeutic doses quickly tends to produce more nausea. The staircase approach lets those pathways adapt.

Each pen contains four weekly doses. Storage is refrigerated at 2–8°C; the pen you are currently using can be kept at room temperature for a limited period, but the exact window is stated in the Patient Information Leaflet and varies by batch, always check that rather than relying on a general figure. A practical note our clinical pharmacy team often passes on: keeping the current pen in the fridge door alongside everyday items makes the weekly injection routine far easier to maintain than treating it as a special occasion.

If you are thinking about what private treatment involves more broadly, the cost and pricing page explains what a transparent private prescription typically covers. And if you want to understand how different approved pharmacies compare on dispensing and supply, our registered pharmacy guide is a useful reference.

Eligibility, licensing and what the pharmacology does not guarantee

Mounjaro is licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 and above where a weight-related condition such as high blood pressure, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea is present. NICE's appraisal (TA1026) recommends tirzepatide for NHS use in adults with a BMI of at least 35 alongside at least one qualifying comorbidity, with lower BMI thresholds for some ethnic backgrounds under UK guidance, and our Mounjaro pharma page sets out the wider pharmaceutical context behind that licensing decision. Private treatment through a regulated service covers a broader population, subject to a prescriber's assessment.

Understanding the pharmacology is genuinely useful, it explains why the titration schedule is what it is, why the side effects cluster in the first weeks, and why a dual-agonist behaves differently from a GLP-1-only medicine. What it cannot do is predict your individual response. Two people at identical doses can have different tolerability profiles and different rates of weight change. That variability is why clinical assessment is not a formality. A prescriber at a service like ours reviews your answers in full, the same day, before anything is approved. If you would like to find out whether you are a candidate, our treatment page is the starting point; there is no cost to the initial consultation.